brexucabtagene autoleucel · Medicine question

When do circulating CAR T-cell levels peak after Tecartus (brexucabtagene autoleucel) infusion in patients with mantle cell lymphoma?

iatroX medicinesPublished 8 November 2026

The answer

Answer

In patients with mantle cell lymphoma in ZUMA-2, circulating anti-CD19 CAR T-cell levels peaked 7–15 days after infusion of Tecartus (brexucabtagene autoleucel) at 2 × 10⁶ anti-CD19 CAR T cells/kg.

Sources for this answer

TecartusGilead Sciences Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 18Document updated 8 September 2026

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about brexucabtagene autoleucel